FDA Drug recall D-0608-2025
Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy
- FDA Drug
- Class II
- ongoing
- Published 2025-09-10
On 2025-09-10 the FDA classified a Class II recall of Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy by Boothwyn Pharmacy, citing subpotent Drug.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0608-2025 |
| Classification | Class II |
| Status | ongoing |
| Initiated | 2025-07-09 |
| Published | 2025-09-10 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Boothwyn Pharmacy |
| Distribution | US |
Product
Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy
Reason
Subpotent Drug
Identifiers
| code_info | 03202025@9 BUD 07/18/2025 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0608-2025%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.